Please also visit GetIPT.com

Site outline:
Choosing IPT
Find a Doctor
IPT Training
About IPT
Other Diseases
Doctors Listing
Patient Stories
Patients Home
Articles & pubs
Site Index
About Us
Tell a Friend

This level:  
Press & Media
Pharma Co's






    Main sections of this site    

About IPT -- Start here.  Definition of IPT, IPT at a glance, IPT method, How IPT works, IPT experience.  Includes IPT History -- discovery & origins, 50s-60s, 70s-80s-90s, IPT millennium.
Cancer -- cases --  breast, prostate, lymphoma, cervix/uterus, skin, bone, pancreas, colon, nose & throat, other cancers
Other Diseases -- cases & possibilities -- arthritis, infectious, respiratory, circulatory/cardiovascular, immune/allergy, neurological, eyes, ears, skin, digestive, genitourinary, musculoskeletal, and more...
Doctors -- currently practicing IPT, and from the past.
Patient Stories -- Interviews with and stories of IPT patients.
Articles & Publications -- articles, documents, patents, bibliography
Books -- Three books about IPT, in English, Spanish, and French.
Action!  -- The road ahead for IPT: advocacy, action, change


Open letter to people at pharmaceutical companies...   

Dear friends,

        This website is about a remarkable medical discovery that you may not be aware of yet.  A simple medical procedure involving a pulse of hypoglycemia, created by insulin followed by glucose...

  1. Can improve drug delivery into cells, across the blood-brain barrier, and into less accessible compartments of the body.
  2. Can greatly improve effectiveness of drugs, allowing them to be given in smaller doses, or in regular doses with stronger effects.
  3. Reduces or eliminates toxic side effects of drugs.
  4. Probably stimulates other beneficial insulin-influenced phenomena such as angiogenesis, detoxification, stem cell proliferation, etc.
  5. Has been applied with a wide range of drugs for treatment of several types of cancer and for a wide variety of other diseases.

        This medical procedure is insulin potentiation therapy (IPT).  We think it may be a medical discovery of great significance, on the level of the discoveries of vaccination, antibiotics, and insulin itself.  I call IPT "The second discovery of insulin."  It has the potential to help millions of people worldwide each year.

        The history if IPT is very interesting, and is marked by three  main facts:

  1. It was discovered in 1926, 75 years ago, and developed empirically..
  2. It has been continuously practiced with great success by a small but growing number of private doctors.
  3. Despite continuing efforts of these doctors to communicate their successes to pharma companies and government agencies, proper and adequate IPT research has not yet been done or funded.

        What are the reasons for this third fact?  Why has no drug company yet taken concerted action to study and implement IPT?   If you have some new insights into the reasons, or have some historical information to disclose, please let me know.  In the mean time, my working hypothesis is that each drug company to which IPT was disclosed dropped the idea for the simple reason that it did not fit in with their business model.  IPT is a method, not a new drug, and so is difficult to convert into cash flow.  And a reduction of drug dose commonly used in IPT could be temporarily disruptive to drug markets and might affect short term profits.  The easiest path was to just walk away from IPT and forget it.

        This is understandable.  Pharmaceutical companies exist to bring profits to their shareholders.  And in current financial markets, companies are especially focused on short-term profits.  

        But pharmaceutical companies also have a responsibility to the human race, of which their employees and stockholders are members.  If IPT is what we think it is, the simple ignorance of it has had many consequences --- very large ones.  It is possible that 75 years of ignorance of IPT has cost humanity trillions of dollars and millions of lives.  Comparable to the effects of a major war.  Conversely, it is possible that IPT research and widespread implementation could earn humanity trillions of dollars of shared wealth, and save millions of lives.

        My goal in this letter is to suggest to you that  investment in IPT research and development is now in your best interest.  The humanitarian reasons should be enough.  But here are ten business reasons.

  1. Good public relations.  IPT information is now readily available on the Internet, and is beginning to appear in the press.  People are finding out about IPT, and will demand that research and implementation begin.  Just as with environmental research among industrial companies, IPT research could become an essential part of corporate citizenship among pharma companies.

  2. Basic science.  If IPT is a real phenomenon, then it is clearly tapping some deep and important mechanisms in the body that are not yet well understood.  Investigation of IPT would result in a better understanding of these mechanisms, opening up opportunities for new drug development.

  3. New large non-diabetic market for insulin.  This should interest Lilly, Novo Nordisk, Pfizer, and any other insulin manufacturers.  One or more of them could also partner with other drug companies for the next items...

  4. Extend patents of existing drugs...  by packaging drugs with insulin or glucose for use in IPT, or by adding IPT to the list of approved uses, or by using other IPT-related packaging or delivery concepts.

  5. Better use of existing drugs.  Improved delivery and effectiveness, with reduced or eliminated toxicity, could enable drugs to reach their full potential. 
  6. New applications for existing drugs.   Improved delivery and effectiveness of drugs with IPT may make them suitable for applications which were not possible or practical before.

  7. Revive drugs rejected for toxicity.   Most drug candidates are rejected, even after costly investment.  IPT can reduce or eliminate toxic side effects, perhaps making these drugs attractive candidates again.

  8. Develop new drugs optimized to work with IPT.  Take advantage of this improved delivery method.

  9. Higher profit per dose.  At least in the US, packaging of smaller drug doses for IPT use could result in a higher profit per dose.

  10. Open larger markets.  Smaller drug doses at lower cost could greatly expand markets in developing countries and among the poor in rich countries.

        These are just preliminary ideas.  You no doubt have a large staff of creative new business development people who can certainly come up with more reasons for you to get into research and implementation of IPT, now that it is entering public consciousness, and won't go away.  On deep analysis, I think you will find that, while IPT might cause some minor market disruptions in the short term, it will help increase your profits, product success, and public approval in the long term.

        And so, with that introduction, I invite you to explore the IPTQ.org website.  I suggest that you read it all.  Read about things that were presented to your predecessors in the past seven and a half decades.  They took a look, quietly closed the book, and walked away.  Now is your chance to make up for their shortsighted behavior.  Humanity is waiting for you to take this action based on both purely commercial interests and higher ethical principles.  We will all benefit.


Chris Duffield  Ph.D.
IPTQ.org webhost


Hit Counter


This level: Up ] Patients ] Public ] Physicians ] Researchers ] Philanthropists ] Press & Media ] Providers ] [ Pharma Co's ] 

Site index: Home ] Choosing IPT ] Find a Doctor ] IPT Training ] . ] About IPT ] Cancer ] Other Diseases ] Doctors Listing ] First Doctors ] Patient Stories ] Patients Home ] Articles & pubs ] Books ] Action ! ] . ] News ] Search ] Site Index ] . ] About Us ] Links ] Tell A Friend ]

Tell a friend about IPTQ.com
Entire IPTQ website Copyright 1999-2002 by Chris Duffield, Ph.D.  All rights reserved.
IPTQ, IPTQ.org, IPTQ.com, IPTQ.net, The second discovery of insulin, and IPTQ lifering and lifeboat logos are trademarks. 
Please read the IPTQ.com disclaimer.   
This page was last updated on  March 19, 2008.
Website technical corrections and suggestions -- email to IPTQ Webhost.
Please also visit GetIPT.com
website visitors since August 2002
Click on box for detailed statistics)

Chris Duffield, webhost